Hookipa Pharma (HOOK) News Today $6.15 -0.17 (-2.69%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 26 at 3:49 PM | marketbeat.comHookipa Pharma (NASDAQ:HOOK) PT Lowered to $23.00JMP Securities cut their target price on shares of Hookipa Pharma from $50.00 to $23.00 and set a "market outperform" rating on the stock in a report on Friday.July 26 at 7:28 AM | marketbeat.comHookipa Pharma Inc (NASDAQ:HOOK) Forecasted to Earn Q2 2024 Earnings of ($1.48) Per ShareHookipa Pharma Inc (NASDAQ:HOOK - Free Report) - Leerink Partnrs upped their Q2 2024 EPS estimates for Hookipa Pharma in a research note issued on Wednesday, July 24th. Leerink Partnrs analyst A. Berens now forecasts that the company will post earnings per share of ($1.48) for the quarter, up froJuly 26 at 5:45 AM | markets.businessinsider.comOptimistic Outlook for Hookipa Pharma’s Oncology Pipeline Prompts Buy RatingJuly 23 at 10:04 AM | finanznachrichten.deHOOKIPA Pharma Inc.: HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200July 22, 2024 | globenewswire.comHOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200July 11, 2024 | marketbeat.comShort Interest in Hookipa Pharma Inc (NASDAQ:HOOK) Decreases By 85.7%Hookipa Pharma Inc (NASDAQ:HOOK - Get Free Report) was the recipient of a large decline in short interest in June. As of June 30th, there was short interest totalling 64,800 shares, a decline of 85.7% from the June 15th total of 453,000 shares. Based on an average trading volume of 88,300 shares, the short-interest ratio is currently 0.7 days. Approximately 0.8% of the shares of the company are sold short.July 11, 2024 | marketbeat.comHookipa Pharma (NASDAQ:HOOK) Sees Unusually-High Trading VolumeHookipa Pharma (NASDAQ:HOOK) Sees Strong Trading VolumeJuly 8, 2024 | marketbeat.comHookipa Pharma (NASDAQ:HOOK) Shares Scheduled to Reverse Split on Wednesday, July 10thHookipa Pharma Inc (NASDAQ:HOOK - Free Report) shares are going to reverse split before the market opens on Wednesday, July 10th. The 1-10 reverse split was announced on Wednesday, July 10th. The number of shares owned by shareholders will be adjusted after the market closes on Wednesday, July 10th.July 8, 2024 | globenewswire.comHOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock SplitJuly 6, 2024 | marketbeat.comHookipa Pharma (NASDAQ:HOOK) Trading Down 2.4%Hookipa Pharma (NASDAQ:HOOK) Shares Down 2.4%July 1, 2024 | globenewswire.comHOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIVJune 5, 2024 | marketbeat.comHC Wainwright Increases Hookipa Pharma (NASDAQ:HOOK) Price Target to $6.00HC Wainwright raised their target price on Hookipa Pharma from $5.00 to $6.00 and gave the company a "buy" rating in a report on Wednesday.June 4, 2024 | globenewswire.comHOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual MeetingJune 1, 2024 | marketbeat.comShort Interest in Hookipa Pharma Inc (NASDAQ:HOOK) Increases By 28.4%Hookipa Pharma Inc (NASDAQ:HOOK - Get Free Report) was the target of a large increase in short interest in May. As of May 15th, there was short interest totalling 826,200 shares, an increase of 28.4% from the April 30th total of 643,700 shares. Based on an average daily trading volume, of 854,300 shares, the short-interest ratio is currently 1.0 days. Currently, 1.1% of the shares of the stock are sold short.May 30, 2024 | globenewswire.comHOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual MeetingMay 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Hookipa Pharma Amid Positive HB-200 Vaccine Trials and Robust Financial PositionMay 23, 2024 | globenewswire.comHOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual MeetingMay 21, 2024 | markets.businessinsider.comDeep Dive Into HOOKIPA Pharma Stock: Analyst Perspectives (4 Ratings)May 21, 2024 | marketbeat.comHookipa Pharma's (HOOK) Outperform Rating Reaffirmed at Royal Bank of CanadaRoyal Bank of Canada reaffirmed an "outperform" rating and set a $5.00 target price on shares of Hookipa Pharma in a research report on Tuesday.May 16, 2024 | investorplace.comPenny Stock Sleepers: 7 Under-the-Radar Gems Ready to LaunchMay 13, 2024 | marketbeat.comHookipa Pharma Inc (NASDAQ:HOOK) Short Interest Up 103.3% in AprilHookipa Pharma Inc (NASDAQ:HOOK - Get Free Report) was the recipient of a large growth in short interest in April. As of April 30th, there was short interest totalling 643,700 shares, a growth of 103.3% from the April 15th total of 316,700 shares. Approximately 0.9% of the company's shares are short sold. Based on an average daily volume of 782,800 shares, the short-interest ratio is presently 0.8 days.May 11, 2024 | finance.yahoo.comHOOKIPA Pharma First Quarter 2024 Earnings: Beats ExpectationsMay 10, 2024 | marketbeat.comHookipa Pharma (NASDAQ:HOOK) Announces Quarterly Earnings ResultsHookipa Pharma (NASDAQ:HOOK - Get Free Report) issued its earnings results on Thursday. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.12) by $0.24. The company had revenue of $36.60 million during the quarter, compared to analyst estimates of $3.20 million. Hookipa Pharma had a negative return on equity of 72.30% and a negative net margin of 405.28%. During the same quarter last year, the business posted ($0.27) EPS.May 9, 2024 | finanznachrichten.deHOOKIPA Pharma Inc.: HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 9, 2024 | globenewswire.comHOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 8, 2024 | marketbeat.comHookipa Pharma (HOOK) Scheduled to Post Quarterly Earnings on ThursdayHookipa Pharma (NASDAQ:HOOK) will be releasing earnings before the market opens on Thursday, May 9, Zacks reports.April 27, 2024 | finanznachrichten.deHOOKIPA Pharma Inc.: HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with PembrolizumabApril 26, 2024 | markets.businessinsider.comBreaking Down HOOKIPA Pharma: 4 Analysts Share Their ViewsApril 25, 2024 | globenewswire.comHOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with PembrolizumabApril 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Hookipa Pharma Amidst Promising Pipeline and Strategic AdvancementsApril 24, 2024 | globenewswire.comHOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated CancersApril 17, 2024 | finanznachrichten.deHOOKIPA Pharma Inc.: HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)April 16, 2024 | finance.yahoo.comHOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)April 10, 2024 | globenewswire.comHOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to RegistrationApril 1, 2024 | marketbeat.comHookipa Pharma Inc (NASDAQ:HOOK) Sees Significant Growth in Short InterestHookipa Pharma Inc (NASDAQ:HOOK - Get Free Report) saw a significant growth in short interest in March. As of March 15th, there was short interest totalling 333,400 shares, a growth of 11.3% from the February 29th total of 299,500 shares. Based on an average daily trading volume, of 2,410,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.6% of the shares of the company are sold short.March 27, 2024 | markets.businessinsider.comOptimistic Buy Rating for Hookipa Pharma Based on Promising HB-200 Trial Results and Strategic Trial DesignMarch 26, 2024 | marketbeat.comHookipa Pharma Inc (NASDAQ:HOOK) Expected to Post FY2028 Earnings of $0.31 Per ShareHookipa Pharma Inc (NASDAQ:HOOK - Free Report) - Equities research analysts at HC Wainwright issued their FY2028 EPS estimates for Hookipa Pharma in a note issued to investors on Monday, March 25th. HC Wainwright analyst A. He expects that the company will post earnings of $0.31 per share for theMarch 25, 2024 | marketbeat.comHookipa Pharma's (HOOK) "Outperform" Rating Reaffirmed at Royal Bank of CanadaRoyal Bank of Canada reiterated an "outperform" rating and set a $5.00 price objective on shares of Hookipa Pharma in a report on Monday.March 24, 2024 | finanznachrichten.deHOOKIPA Pharma Inc.: HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsMarch 24, 2024 | finance.yahoo.comTime To Worry? Analysts Just Downgraded Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) OutlookMarch 23, 2024 | benzinga.comHOOKIPA Pharma Stock (NASDAQ:HOOK), Earnings Estimates, EPS, and RevenueMarch 23, 2024 | markets.businessinsider.comBuy Rating Affirmed for Hookipa Pharma on Emerging Oncology and Infectious Disease PipelinesMarch 22, 2024 | msn.comHOOKIPA Pharma GAAP EPS of -$0.22 misses by $0.02, revenue of $7.41M beats by $2.85MMarch 22, 2024 | globenewswire.comHOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsMarch 6, 2024 | globenewswire.comHOOKIPA Pharma to Participate in Leerink Partners Global Biopharma ConferenceMarch 1, 2024 | marketbeat.comHookipa Pharma (NASDAQ:HOOK) Stock Price Down 4%Hookipa Pharma (NASDAQ:HOOK) Trading Down 4%February 28, 2024 | morningstar.comHOOKIPA Pharma Inc HOOKFebruary 22, 2024 | benzinga.comHOOKIPA Pharma Stock (NASDAQ:HOOK) Dividends: History, Yield and DatesFebruary 2, 2024 | finance.yahoo.comAll You Need to Know About HOOKIPA Pharma Inc. (HOOK) Rating Upgrade to Strong BuyFebruary 1, 2024 | markets.businessinsider.comMaintaining Buy Rating on Hookipa Pharma Amid Strategic Repositioning and Pipeline Promise Get Hookipa Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for HOOK and its competitors with MarketBeat's FREE daily newsletter. Email Address How a $0.25 cent option contract makes my top traders feel (Ad)If you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently… Click now to see for yourself what $0.25 Cent Trades is all about HOOK Media Mentions By Week HOOK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HOOK News Sentiment▼0.460.62▲Average Medical News Sentiment HOOK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HOOK Articles This Week▼91▲HOOK Articles Average Week Get Hookipa Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for HOOK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Gritstone bio News Today Prelude Therapeutics News Today Nanobiotix News Today Design Therapeutics News Today Aldeyra Therapeutics News Today 2seventy bio News Today 23andMe News Today Acrivon Therapeutics News Today ESSA Pharma News Today Immutep News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HOOK) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hookipa Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Hookipa Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.